Next 10 |
Boca Raton, FL, May 25, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company targeting novel treatments for rare diseases, filed its Q1 quarterly report for the period...
Connectyx Technologies Holdings Group, Inc. (CTYX): FY GAAP EPS of $0.0002.Revenue of $0MShares -0.56%.Press Release For further details see: Connectyx Technologies Holdings Group, Inc. reports FY results
Biotechnology Company Issues Highlights and Subsequent Events Boca Raton, Fla, March 09, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on ...
Connectyx Technologies ([[CTYX]] -7.9%) names Richard Garr, former president and chief of clinical-stage biopharma company Neuralstem, as the company's new chief executive officer.The company also announced appointments of Ron Bordens as executive vice president of technical op...
Connectyx Announces Key Biotech Industry Veterans to Management Team Expertise in Clinical Development, Regulatory Affairs and Manufacturing Represented PR Newswire BOCA RATON, Fla. , Feb. 11, 2021 /PRNewswire/ -- Connectyx Technologies Holdings Group, I...
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease PR Newswire BOCA RATON, Fla. , Feb. 4, 2021 /PRNewswire/ -- Connectyx Technologies Holdings Group, Inc. (O...
Initial Biotechnology Portfolio Includes Therapies for Glioblastoma and Late Stage Rabies Boca Raton, FL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biome...
Boca Raton, FL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an ...
OTC listed Connectyx Technologies ([[CTYX]] +24.1%) has agreed to acquire worldwide rights for IMT504, an immunotherapy, to treat symptomatic rabies, from Mid-Atlantic BioTherapeutics."Our goal is to be in the clinic by Q1 2022. As a result of the near 100% fatality rate in late-sta...
Boca Raton, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Com...
News, Short Squeeze, Breakout and More Instantly...
Curative Biotechnology Inc Company Name:
CTYX Stock Symbol:
OTCMKTS Market:
Boca Raton, FL, May 25, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company targeting novel treatments for rare diseases, filed its Q1 quarterly report for the period...
Biotechnology Company Issues Highlights and Subsequent Events Boca Raton, Fla, March 09, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on ...
Connectyx Announces Key Biotech Industry Veterans to Management Team Expertise in Clinical Development, Regulatory Affairs and Manufacturing Represented PR Newswire BOCA RATON, Fla. , Feb. 11, 2021 /PRNewswire/ -- Connectyx Technologies Holdings Group, I...